Paperonium

← Back to the plain-language case

Abstract reverses the direction of the paper's own DDIT4 and gastric cancer survival finding

Gastroenterology (2020) · doi:10.1053/j.gastro.2020.09.016 · PMC7857017

Summary

The abstract states that "Lower DDIT4 expression correlated with longer survival" in gastric cancer. The rest of the paper reports the opposite for the only gastric cancer survival cohort it analyses, a tissue microarray (TMA) of 509 patients. The Introduction, Results, Figure 4 title and Discussion all say that high DDIT4 goes with longer survival, and the Kaplan-Meier curves in Figure 4B agree: the DDIT4-positive group (n = 200) lies above the DDIT4-negative group (n = 309), log-rank P = .021. The reversed sentence is also in the copyedited abstract indexed in PubMed, and no correction has been issued, so readers who see only the abstract get the direction of the paper's main human result backwards.

What the paper reports

Abstract, Results (PMC author manuscript):

Lower DDIT4 expression correlated with longer survival of gastric cancer patients.

Abstract, Results, as deposited in PubMed (PMID 32956680) and Europe PMC, in the journal's copyedited wording:

Lower DDIT4 expression correlated with longer survival of patients with gastric cancer.

Abstract, Conclusions:

During injury-induced metaplastic proliferation, failure of licensing mTORC1 reactivation correlates with increased proliferation of cells harboring DNA damage, as well as increased tumor formation and growth in mice and humans.

Introduction, final (5th) paragraph:

Patients with low expression have poorer survival.

Results, section "Loss of DDIT4 causes cell-autonomous increased growth of human gastric…", paragraph 1:

We examined another annotated tissue microarray on which we had compiled 509 patients with gastric cancer. We saw statistically significant correlation of high DDIT4 expression with increased patient survival and more differentiated tumors, especially in patients who had received chemotherapy, consistent with DDIT4 slowing proliferation in response to DNA damage (Figure 4A–C; Table S3).

Figure 4 title:

In humans, loss of DDIT4 correlates with worse gastric cancer survival and causes cell-autonomous increased mTORC1 and proliferation despite chemotherapy

Figure 4 legend, panel B:

Overall survival determined via Kaplan-Meier curves separated by DDIT4 expression, with an event defined as a cancer-related death.

Discussion, paragraph 3:

Our results showing DDIT4 expression correlating with less proliferation in precancerous lesions and better survival of patients with gastric cancer confirm and extend on those of a previous report43.

Discussion, paragraph 4:

Paradoxically, however, studies across multiple organs have shown disparate results for DDIT4 in tumorigenesis with some studies showing higher DDIT4 decreases cancer survival44, 47–50.

Figure 4B and 4C, legend boxes printed on the image (read from the PMC image file nihms-1661019-f0004.jpg, not from the text):

4B, Overall Patients: DDIT4 negative (n=309); DDIT4 positive (n=200); P = .021

4C, Patients receiving chemotherapy: DDIT4 negative (n=263); DDIT4 positive (n=170); P = .016

What the paper's own numbers show

Method. The paper reports no hazard ratio or survival estimate in its text, so there is no estimate to recompute. Instead I recorded the direction of the DDIT4 and survival association in every place the paper describes it, and checked the group sizes printed on Figure 4B and 4C against the cohort size in the Results. All quotes from the paper's text were matched verbatim against the PMC-archived text, and recompute.py.txt repeats this check for every one of them; the PubMed wording was checked against the PubMed efetch record, and the Figure 4B and 4C counts were read from the figure image. In Figure 4B and 4C the DDIT4-positive curve lies above the DDIT4-negative curve over most of follow-up. In this paper, "positive" is the high-expression group (Figure 4A shows cores scored "negative" or "positive").

Quantity Location Reported Recomputed / what the paper's own material shows
Direction of DDIT4 and survival Abstract, Results (PMC and PubMed) Low DDIT4 → longer survival Opposite to every statement below and to Figure 4B
Direction of DDIT4 and survival Introduction, final (5th) paragraph Low DDIT4 → poorer survival High DDIT4 → longer survival
Direction of DDIT4 and survival Results, 509-patient TMA High DDIT4 → increased survival High DDIT4 → longer survival
Direction of DDIT4 and survival Figure 4 title Loss of DDIT4 → worse survival High DDIT4 → longer survival
Direction of DDIT4 and survival Discussion, paragraph 3 DDIT4 expression → better survival High DDIT4 → longer survival
Direction of DDIT4 and survival Figure 4B and 4C curves Positive curve above negative curve High DDIT4 → longer survival
Body statements that agree Intro, Results, Fig 4 title, Discussion, Fig 4B n/a 5 of 5 agree with each other; the abstract contradicts all 5
Cohort size Results text vs Figure 4B 509 patients; 309 + 200 309 + 200 = 509 (matches)
Chemotherapy subgroup Figure 4C 263 + 170 433 patients, 85.1% of the 509
DDIT4-positive share Figure 4B / 4C 200 of 509; 170 of 433 39.3% in both
Log-rank P Figure 4B / 4C .021 / .016 Not recomputable from published material (no individual data)

Figure

The abstract sentence (orange) and the five places in the body of the paper (blue) that describe the same 509-patient survival result, joined by a connector marking the opposite direction

Figure 1. On the left (orange outline) is the abstract's Results sentence, quoted from the PMC author manuscript; the same sentence, in copyedited wording ("…of patients with gastric cancer"), is in the publisher-deposited abstract in PubMed. On the right (blue outline) are short excerpts from the Introduction, the Results, the Figure 4 title and the Discussion, plus the group sizes and log-rank P value printed on Figure 4B. They describe the same 509-patient gastric cancer tissue microarray (the Introduction sentence does not name the cohort, but the 509-patient TMA is the paper's only survival analysis) and the same endpoint (overall survival, with cancer-related death as the event). The abstract states that low DDIT4 goes with longer survival. Every body statement, and the Kaplan-Meier data, state or show that high DDIT4 goes with longer survival. The counts come from recompute.py.txt, which transcribes them from the Figure 4 image. The paper's own figure is not reproduced.

Why it matters

Explanations considered

Status

Suggested correction

  1. Change the abstract's Results sentence so that it matches the body of the paper and Figure 4B, for example: "Higher DDIT4 expression correlated with longer survival of patients with gastric cancer." The equivalent "Lower DDIT4 expression correlated with shorter survival…" would also work.
  2. Ideally, add the effect size to the abstract and Results (for example a hazard ratio with a 95% CI from a Cox model, alongside the log-rank P = .021 for the 509 patients), so the size and direction of the association can be read without the figure.
  3. Ask PubMed and Europe PMC to update their abstract records when the correction is published, since those are the copies most readers see.